ZyVersa Therapeutics is making strides with its Inflammasome ASC Inhibitor IC 100, aimed at tackling chronic inflammatory diseases, with an initial concentration on obesity-related cardiometabolic conditions. CEO Stephen Glover outlines plans for expanding its indication to include neurodegenerative diseases such as Parkinson’s and Alzheimer’s, as well as multiple sclerosis.
The market for anti-inflammatory biologics is anticipated to see substantial growth, climbing from $105 billion in 2024 to $186 billion by 2034. This increase is largely driven by the growing incidence of chronic inflammatory conditions linked to aging populations, lifestyle changes, and environmental impacts. The burgeoning market and ZyVersa's novel approach targeting the innate immune system have sparked strategic collaborations and mergers and acquisitions, with over $7 billion in deals recorded over the past five years.
Inflammasome research has revealed the significant role of dysregulated inflammasome activation in disease, propelling developers to explore diverse disease targets. ZyVersa's unique approach with IC 100 aims to not only inhibit inflammation initiation but also its progression by targeting ASC and ASC specks. This strategy is expected to achieve superior control over inflammation by impacting multiple inflammasomes.
ZyVersa plans to initiate a proof-of-concept study for IC 100 in the first half of 2025 using a diet-induced obesity mouse model. The study will evaluate the impact on inflammatory and cardiometabolic biomarkers, including insulin resistance, and compare outcomes with semaglutide. Preliminary results are anticipated in the latter half of 2025, followed by an Investigational New Drug Application and a subsequent Phase 1 trial in overweight individuals with cardiometabolic risk factors. Data on safety and biomarker changes are expected by mid-2026.
Additionally, a preclinical study funded by The Michael J. Fox Foundation has been completed, assessing IC 100's potential in treating Parkinson’s disease. A manuscript detailing these findings is in the publication process. ZyVersa has also submitted a grant request for further preclinical studies, with a decision expected by June 2025.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for ZyVersa Therapeutics Inc (ZVSA, Financial) is $120.00 with a high estimate of $120.00 and a low estimate of $120.00. The average target implies an upside of 16,849.15% from the current price of $0.71. More detailed estimate data can be found on the ZyVersa Therapeutics Inc (ZVSA) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, ZyVersa Therapeutics Inc's (ZVSA, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
